ReviewIntestinal research2014
Clinical application of genetics in management of colorectal cancer.
Review in Intestinal research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 43 citations in OpenAlex.
- Survival of colorectal cancer patients in Brunei Darussalam: comparison between 2002-09 and 2010-17.BMC cancer · 2021Article
- Effect ofJournal of gastrointestinal oncology · 2019Article
- Genetic and epigenetic alterations of colorectal cancer.Intestinal research · 2018Review
- Three-year colonoscopy surveillance after polypectomy in Korea: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter prospective study.Intestinal research · 2018Article
- Obesity-related parameters and colorectal adenoma development.Journal of gastroenterology · 2017Article
- Is methylation analysis ofIntestinal research · 2017Article
- The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance.British journal of cancer · 2017Article
- Expression of inositol-requiring enzyme 1β is downregulated in colorectal cancer.Oncology letters · 2017Article
- Filamin A interacting protein 1-like expression inhibits progression in colorectal cancer.Oncotarget · 2016Article
- Field Cancerization in Sporadic Colon Cancer.Gut and liver · 2016Article
- Does Low Threshold Value Use Improve Proximal Neoplasia Detection by Fecal Immunochemical Test?Digestive diseases and sciences · 2016Article
- Myofibroblasts of the muscle layer stimulate the malignant potential of colorectal cancer.Oncology reports · 2016Article
- Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer.Oncotarget · 2016Article
- Risk of Advanced Colorectal Neoplasia According to the Number of High-Risk Findings at Index Colonoscopy: A Korean Association for the Study of Intestinal Disease (KASID) Study.Digestive diseases and sciences · 2016Article
- Article
- Risk Factors Such as Male Sex, Smoking, Metabolic Syndrome, Obesity, and Fatty Liver Do Not Justify Screening Colonoscopies Before Age 45.Digestive diseases and sciences · 2016Article
- Risk of Colorectal Neoplasia According to Fatty Liver Severity and Presence of Gall Bladder Polyps.Digestive diseases and sciences · 2016Article
- Correlational research of Golgi phosphorylation protein 3 expression in colorectal cancer.World journal of gastroenterology · 2015Article
- Clinical Features and Prognosis of Resectable Primary Colorectal Signet-Ring Cell Carcinoma.Intestinal research · 2015Article
- Associations Between Parameters of Glucose and Lipid Metabolism and Risk of Colorectal Neoplasm.Digestive diseases and sciences · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The extensive study of genetic alterations in colorectal cancer (CRC) has led to molecular diagnostics playing an increasingly important role in CRC diagnosis and treatment. Currently, it is believed that CRC is a consequence of the accumulation of both genetic and epigenetic genomic alterations. It is known that there are at least 3 major pathways that lead to colorectal carcinogenesis: (1) the chromosomal instability pathway, (2) the microsatellite instability pathway, and (3) the cytosine-phospho-guanine island methylator phenotype pathway. With recent advances in CRC genetics, the identification of specific molecular alterations responsible for CRC pathogenesis has directly influences clinical care. Patients at high risk for developing CRC can be identified by genetic testing for specific molecular alterations, and the use of molecular biomarkers for predictive and prognostic purposes is also increasing. This is clearly supported by the recent advances in genetic testing for CRC whereby specific molecular alterations are identified for the purpose of guiding treatment with targeting therapies such as anti-endothelial growth factor receptor monoclonal antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.